Blood counts of WT and Egr1-deficient mice after treatment with ENU
| Group . | n (%) . | WBC, ×109/L . | RBC, ×1012/L . | HGB, g/L . | HCT, % . | MCV, fL . | MCH, pg . | MCHC, g/L . | RDW, % . | PLT, ×109/L . |
|---|---|---|---|---|---|---|---|---|---|---|
| Disease-free | ||||||||||
| 4 wk | ||||||||||
| WT | 8 (53) | 16.4 ± 1.6 | 8.9 ± 0.5 | 135 ± 9 | 42.5 ± 1.6 | 47.6 ± 1.8 | 15.2 ± 1.3 | 319 ± 31 | 19.0 ± 0.3 | 935 ± 109 |
| Egr1+/− | 1* (7) | 15.58 | 6.88 | 112 | 39.3 | 57.1 | 16.3 | 285 | 24.5 | 941 |
| Egr1−/− | 0 (0) | — | — | — | — | — | — | — | — | — |
| 20 wk | ||||||||||
| WT | 11 (92) | 12.2 ± 4.3 | 8.7 ± 0.8 | 125 ± 15 | 40.8 ± 3.4 | 46.9 ± 4.1 | 14.3 ± 0.9 | 306 ± 18 | 21.7 ± 2.8 | 1022 ± 443 |
| Egr1+/− | 3 (25) | 18.7 ± 0.3 | 10.0 ± 0.6 | 138 ± 11 | 47.5 ± 1.4 | 47.8 ± 4.0 | 13.8 ± 0.3 | 290 ± 31 | 19.9 ± 0.2 | 1500 ± 337 |
| Egr1−/− | 1 (11) | 16.8 | 9.98 | 133 | 44.3 | 44.4 | 13.3 | 300 | 20.5 | 1264 |
| T-cell lymphoma | ||||||||||
| 4 wk | ||||||||||
| WT | 5 (33) | 13.3 ± 4.1 | 8.2 ± 1.4 | 125 ± 14 | 42.8 ± 1.5 | 52.9 ± 8.5 | 15.3 ± 1.2 | 291 ± 23 | 25.3 ± 7.9 | 774 ± 396 |
| Egr1+/− | 9 (60) | 20.2 ± 9.9 | 8.9 ± 1.1 | 132 ± 13 | 44.1 ± 4.2 | 49.9 ± 4.1 | 14.9 ± 0.9 | 300 ± 11 | 24.5 ± 6.9 | 617 ± 241 |
| Egr1−/− | 8 (53) | 22.0 ± 3.1 | 10.1 ± 1.2 | 142 ± 15 | 45.0 ± 6.1 | 44.6 ± 0.9 | 14.2 ± 0.2 | 317 ± 9 | 19.8 ± 1.4 | 658 ± 44.8 |
| 20 wk | ||||||||||
| WT | 1 (8) | 14.4 | 10.38 | 152 | 45.5 | 43.8 | 14.6 | 334 | 18.9 | 837 |
| Egr1+/− | 6 (50) | 14.9 ± 4.0 | 8.1 ± 2.1 | 117 ± 33 | 38.1 ± 7.8 | 47.6 ± 3.5 | 14.4 ± 0.5 | 304 ± 30 | 21.1 ± 2.7 | 880 ± 471 |
| Egr1−/− | 5 (55) | 17.2 ± 2.9 | 8.4 ± 1.6 | 122 ± 18 | 40.6 ± 4.6 | 48.7 ± 4.6 | 14.6 ± 1.6 | 300 ± 12 | 22.2 ± 2.2 | 1000 ± 292 |
| MPD | ||||||||||
| 4 wk | ||||||||||
| WT | 2 (13) | 17.6 ± 9.4 | 5.1 ± 1.9 | 81 ± 33 | 29.1 ± 8.9 | 58.4 ± 4.2 | 15.8 ± 0.7 | 272 ± 31 | 26.0 ± 7.4 | 1127 ± 29 |
| Egr1+/− | 5 (33) | 19.0 ± 4.6 | 3.3 ± 0.5 | 53 ± 12 | 19.8 ± 3.8 | 59.0 ± 4.6 | 15.9 ± 1.8 | 269 ± 14 | 30.5 ± 4.7 | 1263 ± 688 |
| Egr1−/− | 7 (46) | 28.5 ± 3.8 | 4.7 ± 0.8 | 69 ± 21 | 26.5 ± 6.3 | 56.1 ± 4.1 | 14.4 ± 2.2 | 256 ± 23 | 25.7 ± 6.2 | 288.5 ± 217 |
| 20 wk | ||||||||||
| WT | 0 (0) | — | — | — | — | — | — | — | — | — |
| Egr1+/− | 3 (25) | 14.5 ± 7.2 | 4.8 ± 1.4 | 70 ± 23 | 25.8 ± 7.3 | 54.2 ± 5.2 | 14.6 ± 1.7 | 268 ± 12 | 28.8 ± 9.6 | 175 ± 34 |
| Egr1−/− | 3 (33) | 19.4 ± 1.9 | 5.2 ± 0.2 | 75 ± 1 | 28.1 ± 2.1 | 53.7 ± 6.4 | 14.4 ± 0.9 | 268 ± 15 | 23.6 ± 0.6 | 727 ± 304 |
| Group . | n (%) . | WBC, ×109/L . | RBC, ×1012/L . | HGB, g/L . | HCT, % . | MCV, fL . | MCH, pg . | MCHC, g/L . | RDW, % . | PLT, ×109/L . |
|---|---|---|---|---|---|---|---|---|---|---|
| Disease-free | ||||||||||
| 4 wk | ||||||||||
| WT | 8 (53) | 16.4 ± 1.6 | 8.9 ± 0.5 | 135 ± 9 | 42.5 ± 1.6 | 47.6 ± 1.8 | 15.2 ± 1.3 | 319 ± 31 | 19.0 ± 0.3 | 935 ± 109 |
| Egr1+/− | 1* (7) | 15.58 | 6.88 | 112 | 39.3 | 57.1 | 16.3 | 285 | 24.5 | 941 |
| Egr1−/− | 0 (0) | — | — | — | — | — | — | — | — | — |
| 20 wk | ||||||||||
| WT | 11 (92) | 12.2 ± 4.3 | 8.7 ± 0.8 | 125 ± 15 | 40.8 ± 3.4 | 46.9 ± 4.1 | 14.3 ± 0.9 | 306 ± 18 | 21.7 ± 2.8 | 1022 ± 443 |
| Egr1+/− | 3 (25) | 18.7 ± 0.3 | 10.0 ± 0.6 | 138 ± 11 | 47.5 ± 1.4 | 47.8 ± 4.0 | 13.8 ± 0.3 | 290 ± 31 | 19.9 ± 0.2 | 1500 ± 337 |
| Egr1−/− | 1 (11) | 16.8 | 9.98 | 133 | 44.3 | 44.4 | 13.3 | 300 | 20.5 | 1264 |
| T-cell lymphoma | ||||||||||
| 4 wk | ||||||||||
| WT | 5 (33) | 13.3 ± 4.1 | 8.2 ± 1.4 | 125 ± 14 | 42.8 ± 1.5 | 52.9 ± 8.5 | 15.3 ± 1.2 | 291 ± 23 | 25.3 ± 7.9 | 774 ± 396 |
| Egr1+/− | 9 (60) | 20.2 ± 9.9 | 8.9 ± 1.1 | 132 ± 13 | 44.1 ± 4.2 | 49.9 ± 4.1 | 14.9 ± 0.9 | 300 ± 11 | 24.5 ± 6.9 | 617 ± 241 |
| Egr1−/− | 8 (53) | 22.0 ± 3.1 | 10.1 ± 1.2 | 142 ± 15 | 45.0 ± 6.1 | 44.6 ± 0.9 | 14.2 ± 0.2 | 317 ± 9 | 19.8 ± 1.4 | 658 ± 44.8 |
| 20 wk | ||||||||||
| WT | 1 (8) | 14.4 | 10.38 | 152 | 45.5 | 43.8 | 14.6 | 334 | 18.9 | 837 |
| Egr1+/− | 6 (50) | 14.9 ± 4.0 | 8.1 ± 2.1 | 117 ± 33 | 38.1 ± 7.8 | 47.6 ± 3.5 | 14.4 ± 0.5 | 304 ± 30 | 21.1 ± 2.7 | 880 ± 471 |
| Egr1−/− | 5 (55) | 17.2 ± 2.9 | 8.4 ± 1.6 | 122 ± 18 | 40.6 ± 4.6 | 48.7 ± 4.6 | 14.6 ± 1.6 | 300 ± 12 | 22.2 ± 2.2 | 1000 ± 292 |
| MPD | ||||||||||
| 4 wk | ||||||||||
| WT | 2 (13) | 17.6 ± 9.4 | 5.1 ± 1.9 | 81 ± 33 | 29.1 ± 8.9 | 58.4 ± 4.2 | 15.8 ± 0.7 | 272 ± 31 | 26.0 ± 7.4 | 1127 ± 29 |
| Egr1+/− | 5 (33) | 19.0 ± 4.6 | 3.3 ± 0.5 | 53 ± 12 | 19.8 ± 3.8 | 59.0 ± 4.6 | 15.9 ± 1.8 | 269 ± 14 | 30.5 ± 4.7 | 1263 ± 688 |
| Egr1−/− | 7 (46) | 28.5 ± 3.8 | 4.7 ± 0.8 | 69 ± 21 | 26.5 ± 6.3 | 56.1 ± 4.1 | 14.4 ± 2.2 | 256 ± 23 | 25.7 ± 6.2 | 288.5 ± 217 |
| 20 wk | ||||||||||
| WT | 0 (0) | — | — | — | — | — | — | — | — | — |
| Egr1+/− | 3 (25) | 14.5 ± 7.2 | 4.8 ± 1.4 | 70 ± 23 | 25.8 ± 7.3 | 54.2 ± 5.2 | 14.6 ± 1.7 | 268 ± 12 | 28.8 ± 9.6 | 175 ± 34 |
| Egr1−/− | 3 (33) | 19.4 ± 1.9 | 5.2 ± 0.2 | 75 ± 1 | 28.1 ± 2.1 | 53.7 ± 6.4 | 14.4 ± 0.9 | 268 ± 15 | 23.6 ± 0.6 | 727 ± 304 |
WT, Egr1+/−, and Egr1−/− mice, treated with ENU at 4 weeks or 20 weeks of age, were monitored for the onset of disease. Blood was collected just prior to death for CBC analysis. The data reported here are means (± SD). Values shown for mice that were disease-free were obtained at 45 to 60 weeks of age.
WBC indicates white blood cells; RBC, red blood cells; HGB, hemoglobin; HCT, hematocrit; MCV, mean cell volume; MCH, mean cell hemoglobin; MCHC mean cell hemoglobin concentration; RDW, red cell distribution width; PLT, platelets; and —, no mice in treatment.
Mouse presented with a reactive condition.